Search research articles
Contact Us
Filters
Showing results (51-60 of 93) with videos related to
Page
of 10
Sort By:
Blood Cells, Molecules & Diseases
|
November 23, 2017
Hematological phenotypes in children according to the α-globin genotypes
Raffaella Origa, Susanna Barella, Maria Elisabetta Paglietti, et al.
British Journal of Haematology
|
June 1, 2019
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia
Yesim Aydinok, Antonio Piga, Raffaella Origa, et al.
American Journal of Hematology
|
August 30, 2017
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment
Giovanni Caocci, Maria Grazia Orofino, Adriana Vacca, et al.
Health and Quality of Life Outcomes
|
November 21, 2018
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
Ali T Taher, Raffaella Origa, Silverio Perrotta, et al.
European Journal of Haematology
|
January 28, 2014
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
Ali T Taher, John B Porter, Vip Viprakasit, et al.
Journal of Clinical Medicine
|
April 12, 2022
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
Raffaella Origa, Monia Cinus, Maria Paola Pilia, et al.
British Journal of Haematology
|
September 13, 2014
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia
Ali T Taher, John B Porter, Vip Viprakasit, et al.
Internal and Emergency Medicine
|
June 28, 2018
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited
Giorgio Derchi, Carlo Dessì, Patrizio Bina, et al.
American Journal of Hematology
|
February 1, 2017
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study
Ali T Taher, Raffaella Origa, Silverio Perrotta, et al.
Parkinsonism & Related Disorders
|
March 26, 2014
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up
Giovanni Cossu, Giovanni Abbruzzese, Gildo Matta, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 93) with videos related to
Sort By:
Page
of 10
Blood Cells, Molecules & Diseases
|
November 23, 2017
Hematological phenotypes in children according to the α-globin genotypes
Raffaella Origa, Susanna Barella, Maria Elisabetta Paglietti, et al.
British Journal of Haematology
|
June 1, 2019
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia
Yesim Aydinok, Antonio Piga, Raffaella Origa, et al.
American Journal of Hematology
|
August 30, 2017
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment
Giovanni Caocci, Maria Grazia Orofino, Adriana Vacca, et al.
Health and Quality of Life Outcomes
|
November 21, 2018
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
Ali T Taher, Raffaella Origa, Silverio Perrotta, et al.
European Journal of Haematology
|
January 28, 2014
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
Ali T Taher, John B Porter, Vip Viprakasit, et al.
Journal of Clinical Medicine
|
April 12, 2022
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
Raffaella Origa, Monia Cinus, Maria Paola Pilia, et al.
British Journal of Haematology
|
September 13, 2014
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia
Ali T Taher, John B Porter, Vip Viprakasit, et al.
Internal and Emergency Medicine
|
June 28, 2018
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited
Giorgio Derchi, Carlo Dessì, Patrizio Bina, et al.
American Journal of Hematology
|
February 1, 2017
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study
Ali T Taher, Raffaella Origa, Silverio Perrotta, et al.
Parkinsonism & Related Disorders
|
March 26, 2014
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up
Giovanni Cossu, Giovanni Abbruzzese, Gildo Matta, et al.
Page
of 10